{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:52:37Z","timestamp":1784177557206,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prolonged use of broad-spectrum antibiotics disrupts the indigenous gut microbiota, which consequently enables toxigenic <jats:italic>Clostridium difficile<\/jats:italic> species to proliferate and cause infection. The burden of <jats:italic>C. difficile<\/jats:italic> infections was exacerbated with the outbreak of hypervirulent strains that produce copious amounts of enterotoxins and spores. In recent past, membrane-active agents have generated a surge of interest due to their bactericidal property with a low propensity for resistance. In this study, we capitalized on the antimicrobial property and low oral bioavailability of salicylanilide anthelmintics (closantel, rafoxanide, niclosamide, oxyclozanide) to target the gut pathogen. By broth microdilution techniques, we determined the MIC values of the anthelmintics against 16 <jats:italic>C. difficile<\/jats:italic> isolates of defined PCR-ribotype. The anthelmintics broadly inhibited <jats:italic>C. difficile<\/jats:italic> growth <jats:italic>in vitro<\/jats:italic> via a membrane depolarization mechanism. Interestingly, the salicylanilides were bactericidal against logarithmic- and stationary-phase cultures of the BI\/NAP1\/027 strain 4118. The salicylanilides were poorly active against select gut commensals (<jats:italic>Bacteroides<\/jats:italic>, <jats:italic>Bifidobacterium<\/jats:italic> and <jats:italic>Lactobacillus<\/jats:italic> species) and were non-hemolytic and non-toxic to mammalian cell lines HepG2 and HEK 293T\/17 within the range of their <jats:italic>in vitro<\/jats:italic> MICs and MBCs. The salicylanilide anthelmintics exhibit desirable properties for repositioning as anti-<jats:italic>C. difficile<\/jats:italic> agents.<\/jats:p>","DOI":"10.1038\/srep33642","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T09:28:51Z","timestamp":1474018131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Reprofiled anthelmintics abate hypervirulent stationary-phase Clostridium difficile"],"prefix":"10.1038","volume":"6","author":[{"given":"Major","family":"Gooyit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim D.","family":"Janda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,16]]},"reference":[{"key":"BFsrep33642_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa1408913","volume":"372","author":"FC Lessa","year":"2015","unstructured":"Lessa, F. C. et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372, 825\u2013834 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep33642_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1473-3099(05)70215-2","volume":"5","author":"S Aslam","year":"2005","unstructured":"Aslam, S., Hamill, R. J. & Musher, D. M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis. 5, 549\u2013557 (2005).","journal-title":"Lancet Infect. Dis."},{"key":"BFsrep33642_CR3","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1056\/NEJMoa051639","volume":"353","author":"VG Loo","year":"2005","unstructured":"Loo, V. G. et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353, 2442\u20132449 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep33642_CR4","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1128\/JB.00445-10","volume":"192","author":"M Merrigan","year":"2010","unstructured":"Merrigan, M. et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J. Bacteriol. 192, 4904\u20134911 (2010).","journal-title":"J. Bacteriol."},{"key":"BFsrep33642_CR5","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1056\/NEJMra0707500","volume":"359","author":"CP Kelly","year":"2008","unstructured":"Kelly, C. P. & LaMont, J. T. Clostridium difficile\u2013more difficult than ever. N. Engl. J. Med. 359, 1932\u20131940 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep33642_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie, T. J. et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364, 422\u2013431 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep33642_CR7","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1093\/cid\/cis462","volume":"55","author":"OA Cornely","year":"2012","unstructured":"Cornely, O. A., Miller, M. A., Louie, T. J., Crook, D. W. & Gorbach, S. L. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin. Infect. Dis. 55 Suppl 2, S154\u2013S161 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep33642_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1128\/AAC.01443-07","volume":"53","author":"TJ Louie","year":"2009","unstructured":"Louie, T. J., Emery, J., Krulicki, W., Byrne, B. & Mah, M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother. 53, 261\u2013263 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep33642_CR9","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1128\/AAC.48.11.4430-4434.2004","volume":"48","author":"KL Credito","year":"2004","unstructured":"Credito, K. L. & Appelbaum, P. C. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. 48, 4430\u20134434 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep33642_CR10","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1093\/cid\/cis453","volume":"55","author":"F Babakhani","year":"2012","unstructured":"Babakhani, F. et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin. Infect. Dis. 55 Suppl 2, S162\u2013S169 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep33642_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/jac\/dks450","volume":"68","author":"F Babakhani","year":"2013","unstructured":"Babakhani, F. et al. Fidaxomicin inhibits toxin production in Clostridium difficile. J. Antimicrob. Chemother. 68, 515\u2013522 (2013).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep33642_CR12","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1128\/JCM.00524-08","volume":"46","author":"T Pelaez","year":"2008","unstructured":"Pelaez, T. et al. Metronidazole resistance in Clostridium difficile is heterogeneous. J. Clin. Microbiol. 46, 3028\u20133032 (2008).","journal-title":"J. Clin. Microbiol."},{"key":"BFsrep33642_CR13","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1128\/AAC.06257-11","volume":"56","author":"DR Snydman","year":"2012","unstructured":"Snydman, D. R., Jacobus, N. V. & McDermott, L. A. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob. Agents Chemother. 56, 3448\u20133452 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep33642_CR14","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1128\/AAC.00625-11","volume":"55","author":"EJ Goldstein","year":"2011","unstructured":"Goldstein, E. J. et al. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob. Agents Chemother. 55, 5194\u20135199 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep33642_CR15","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.1021\/jm5016846","volume":"58","author":"AM Jarrad","year":"2015","unstructured":"Jarrad, A. M., Karoli, T., Blaskovich, M. A., Lyras, D. & Cooper, M. A. Clostridium difficile drug pipeline: challenges in discovery and development of new agents. J. Med. Chem. 58, 5164\u20135185 (2015).","journal-title":"J. Med. Chem."},{"key":"BFsrep33642_CR16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/jac\/dks493","volume":"68","author":"X Wu","year":"2013","unstructured":"Wu, X., Cherian, P. T., Lee, R. E. & Hurdle, J. G. The membrane as a target for controlling hypervirulent Clostridium difficile infections. J. Antimicrob. Chemother. 68, 806\u2013815 (2013).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep33642_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrmicro2474","volume":"9","author":"JG Hurdle","year":"2011","unstructured":"Hurdle, J. G., O\u2019Neill, A. J., Chopra, I. & Lee, R. E. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat. Rev. Microbiol. 9, 62\u201375 (2011).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFsrep33642_CR18","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1128\/AAC.00275-15","volume":"59","author":"L Bouillaut","year":"2015","unstructured":"Bouillaut, L. et al. Effects of surotomycin on Clostridium difficile viability and toxin production in vitro. Antimicrob. Agents Chemother. 59, 4199\u20134205 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep33642_CR19","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/jac\/dkr201","volume":"66","author":"JG Hurdle","year":"2011","unstructured":"Hurdle, J. G., Heathcott, A. E., Yang, L., Yan, B. & Lee, R. E. Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations. J. Antimicrob. Chemother. 66, 1773\u20131776 (2011).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep33642_CR20","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1021\/jm9803572","volume":"41","author":"MJ Macielag","year":"1998","unstructured":"Macielag, M. J. et al. Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria. J. Med. Chem. 41, 2939\u20132945 (1998).","journal-title":"J. Med. Chem."},{"key":"BFsrep33642_CR21","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.1016\/j.bmc.2013.08.029","volume":"21","author":"K Pauk","year":"2013","unstructured":"Pauk, K. et al. New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species. Bioorg. Med. Chem. 21, 6574\u20136581 (2013).","journal-title":"Bioorg. Med. Chem."},{"key":"BFsrep33642_CR22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4102\/jsava.v70i2.756","volume":"70","author":"GE Swan","year":"1999","unstructured":"Swan, G. E. The pharmacology of halogenated salicylanilides and their anthelmintic use in animals. J. S. Afr. Vet. Assoc. 70, 61\u201370 (1999).","journal-title":"J. S. Afr. Vet. Assoc."},{"key":"BFsrep33642_CR23","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.2174\/138161211798194521","volume":"17","author":"M Kratky","year":"2011","unstructured":"Kratky, M. & Vinsova, J. Salicylanilide ester prodrugs as potential antomicrobial agents\u2013a review. Curr. Pharm. Des. 17, 3494\u20133505 (2011).","journal-title":"Curr. Pharm. Des"},{"key":"BFsrep33642_CR24","doi-asserted-by":"publisher","first-page":"12281","DOI":"10.1073\/pnas.1005485107","volume":"107","author":"H Strahl","year":"2010","unstructured":"Strahl, H. & Hamoen, L. W. Membrane potential is important for bacterial cell division. Proc. Natl. Acad. Sci. USA 107, 12281\u201312286 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep33642_CR25","doi-asserted-by":"publisher","first-page":"11945","DOI":"10.1073\/pnas.0711697105","volume":"105","author":"SP Rao","year":"2008","unstructured":"Rao, S. P., Alonso, S., Rand, L., Dick, T. & Pethe, K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 105, 11945\u201311950 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep33642_CR26","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1128\/AEM.02671-10","volume":"77","author":"MH Tempelaars","year":"2011","unstructured":"Tempelaars, M. H., Rodrigues, S. & Abee, T. Comparative analysis of antimicrobial activities of valinomycin and cereulide, the Bacillus cereus emetic toxin. Appl. Environ. Microbiol. 77, 2755\u20132762 (2011).","journal-title":"Appl. Environ. Microbiol."},{"key":"BFsrep33642_CR27","doi-asserted-by":"publisher","first-page":"e89189","DOI":"10.1371\/journal.pone.0089189","volume":"9","author":"R Rajamuthiah","year":"2014","unstructured":"Rajamuthiah, R. et al. Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus. PLoS One 9, e89189 (2014).","journal-title":"PLoS One"},{"key":"BFsrep33642_CR28","doi-asserted-by":"publisher","first-page":"e0124595","DOI":"10.1371\/journal.pone.0124595","volume":"10","author":"R Rajamuthiah","year":"2015","unstructured":"Rajamuthiah, R. et al. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. PLoS One 10, e0124595 (2015).","journal-title":"PLoS One"},{"key":"BFsrep33642_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0163-7258(82)90064-X","volume":"19","author":"P Andrews","year":"1983","unstructured":"Andrews, P., Thyssen, J. & Lorke, D. The biology and toxicology of molluscicides, Bayluscide. Phamacol. Ther. 19, 245\u2013295 (1983).","journal-title":"Phamacol. Ther"},{"key":"BFsrep33642_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1128\/CMR.00082-09","volume":"23","author":"J Freeman","year":"2010","unstructured":"Freeman, J. et al. The changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 23, 529\u2013549 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"BFsrep33642_CR31","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/cid\/cis614","volume":"55","author":"MH Wilcox","year":"2012","unstructured":"Wilcox, M. H. et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin. Infect. Dis. 55, 1056\u20131063 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep33642_CR32","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1021\/jm5006435","volume":"57","author":"M Gooyit","year":"2014","unstructured":"Gooyit, M., Tricoche, N., Lustigman, S. & Janda, K. D. Dual protonophore-chitinase inhibitors dramatically affect O. volvulus molting. J. Med. Chem. 57, 5792\u20135799 (2014).","journal-title":"J. Med. Chem."},{"key":"BFsrep33642_CR33","doi-asserted-by":"crossref","unstructured":"Riedel, T. et al. Genome resequencing of the virulent and multidrug-resistant reference strain Clostridium difficile 630. Genome Announc. 3 (2015).","DOI":"10.1128\/genomeA.00276-15"},{"key":"BFsrep33642_CR34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1021\/acsinfecdis.5b00017","volume":"1","author":"M Gooyit","year":"2015","unstructured":"Gooyit, M. et al. Onchocerca volvulus molting inhibitors identified through scaffold hopping. ACS Infect. Dis. 1, 198\u2013202 (2015).","journal-title":"ACS Infect. Dis."},{"key":"BFsrep33642_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1021\/ml500516r","volume":"6","author":"M Gooyit","year":"2015","unstructured":"Gooyit, M., Tricoche, N., Javor, S., Lustigman, S. & Janda, K. D. Exploiting the polypharmacology of \u03b2-carbolines to disrupt O. volvulus molting. ACS Med. Chem. Lett. 6, 339\u2013343 (2015).","journal-title":"ACS Med. Chem. Lett."},{"key":"BFsrep33642_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0300-483X(97)00151-0","volume":"124","author":"G Malich","year":"1997","unstructured":"Malich, G., Markovic, B. & Winder, C. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 124, 179\u2013192 (1997).","journal-title":"Toxicology"},{"key":"BFsrep33642_CR37","doi-asserted-by":"publisher","first-page":"iii7","DOI":"10.1093\/jac\/dkn367","volume":"62","author":"PM Hawkey","year":"2008","unstructured":"Hawkey, P. M. Pre-clinical experience with daptomycin. J. Antimicrob. Chemother. 62 Suppl 3, iii7\u201314 (2008).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep33642_CR38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","volume":"70","author":"GG Zhanel","year":"2010","unstructured":"Zhanel, G. G. et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70, 859\u2013886 (2010).","journal-title":"Drugs"},{"key":"BFsrep33642_CR39","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard\u2013Ninth Edition. CLSI Document M07- A9; Wayne, PA, 2012."},{"key":"BFsrep33642_CR40","unstructured":"CLSI. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated Fastidious Bacteria; Approved Guideline\u2013Second Edition. CLSI Document M45- A2; Wayne, PA, 2010."},{"key":"BFsrep33642_CR41","unstructured":"CLSI. Methods for Antimicrobial Susceptibility Testing Anaerobic Bacteria; Approved Standard\u2013Eighth Edition. CLSI Document M11-A8; Wayne, PA, 2012."},{"key":"BFsrep33642_CR42","unstructured":"ISO 10932:2010 Milk and milk products\u2013Determination of the minimal inhibitory concentration (MIC) of antibiotics applicable to bifidobacteria and non-enterococcal lactic acid bacteria. International Organization for Standardization."},{"key":"BFsrep33642_CR43","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1093\/jac\/dkv231","volume":"70","author":"PT Cherian","year":"2015","unstructured":"Cherian, P. T. et al. Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection. J. Antimicrob. Chemother. 70, 3061\u20133069 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep33642_CR44","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1128\/AAC.01087-15","volume":"59","author":"MZ Alam","year":"2015","unstructured":"Alam, M. Z., Wu, X., Mascio, C., Chesnel, L. & Hurdle, J. G. Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile. Antimicrob. Agents. Chemother. 59, 5165\u20135170 (2015).","journal-title":"Antimicrob. Agents. Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep33642","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep33642.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep33642.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T23:30:38Z","timestamp":1672875038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep33642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,16]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,14]]}},"alternative-id":["BFsrep33642"],"URL":"https:\/\/doi.org\/10.1038\/srep33642","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,16]]},"assertion":[{"value":"27 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33642"}}